GlassScriptPhysician profile
Andrea W Rupe
NPI 1942430335
$13,153.85
in general payments reported to CMS, 2019-2025
51 companies · $2,202 in 2025
The $2,202 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,190 · 2022: $2,875 · 2023: $2,768 · 2024: $2,119 · 2025: $2,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,088.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,537.74 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,404.68 | 2021-2025 | |
| Novo Nordisk INC | $1,323.73 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,016.98 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $688.08 | 2021-2025 | Rexulti, Jynarque, Abilify Maintena |
| Abbott Laboratories | $659.41 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $580.61 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $574.19 | 2021-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $533.22 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $373.73 | 2021-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $316.31 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $314.13 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $302.15 | 2021-2025 | Trintellix |
| Dexcom, INC. | $299.23 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $258.26 | 2023-2025 | Cologuard Collection Kit |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Rupe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.